Rigel Pharmaceuticals

@RigelPharma #Hiring - Senior Scientist (Pharmacology) - https://workforcenow.adp.com//recruitment/recruitment.html #biotech #Jobs

@RigelPharma #news Rigel Announces First Patients Enrolled in @NIH_NHLBI Sponsored Trial of #fostamatinib in Hospitalized #COVID__19 Patients in Collaboration with @InovaHealth. Trial being conducted at NIH Clinical Center in Bethesda, Maryland and Inova Fairfax Hospital in Virginia. https://ir.rigel.com//rigel-announces-first-patients-enrol

Inhibiting SYK can help people living with chronic #ITP. Find out if treatment with a SYK inhibitor might be right for you. protectyourplatelets.com #ProtectPlatelets #BeatITP

Today @RigelPharma is all purple. We are dressed to support the ITP community and @PDSA_ITP, and all month we have been spreading the word about ITP and the need for greater support. #BeatITP

Chronic ITP is an #autoimmune disorder where the body’s immune system attacks and destroys blood platelets, which can lead to excessive bleeding and other complications. @RigelPharma raised awareness of #ITP during our @PDSA_ITP virtual walk week. protectyourplatelets.com

@RigelPharma #hiring - HR Operations Associate Director - https://workforcenow.adp.com//recruitment/recruitment.html #biotechjobs #humanresources #jobs #recruiting #careers

Living with chronic #ITP: What are your priorities and goals for treatment? Stopping platelet destruction by inhibiting SYK could help. Take the conversation to your doctor - https://tavalisse.com/rightforyou #ProtectPlatelets #BeatITP protectyourplatelets.com

@RigelPharma #news - @NIH launches trial of Rigel drug for severe COVID-19 https://news.trust.org/item/20200917103923-2r38s/ - #fostamatinib #clinicaltrial #Pharmaceuticals @NIH_NHLBI

Chronic ITP can be a lifelong disorder. September is #ITPAwarenessMonth and @RigelPharma is Standing Strong in support of people living with #ITP, their care partners, and healthcare providers. Learn more about a treatment option for chronic ITP: protectyourplatelets.com

Rigel Pharmaceuticals announces a Phase 2 trial to evaluate the safety of fostamatinib for the treatment of hospitalized COVID-19 patients. The study is sponsored by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), in collaboration with Inova Health System. Learn more: https://ir.rigel.com//rigel-announces-nihnhlbi-sponsored-t

It’s been over 2 years since @RigelPharma gained approval for a chronic ITP treatment that works in a different way. The stories of the patients who are taking it are inspiring. More options mean more opportunities to fight #ITP. Watch Raynelle’s story about ITP and treatment. https://tavalisse.com/info #ProtectingPlatelets #beatITP

@RigelPharma is #Hiring - Executive Director, Biometrics - https://workforcenow.adp.com//recruitment/recruitment.html #Jobs #biometrics #Biotechnology

@RigelPharma is #Hiring - Territory Business Manager (Upstate NY) - https://workforcenow.adp.com//recruitment/recruitment.html #Jobs #biotech #Commercial